Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain.

Strope JD, Peer CJ, Sissung TM, Hall OM, Huang PA, Harris EM, Gustafson KR, Henrich CJ, Sigano DM, Pauly GT, Schneider JP, Bates SE, Figg WD.

Cancer Biol Ther. 2019 Nov 10:1-8. doi: 10.1080/15384047.2019.1683324. [Epub ahead of print]

PMID:
31709896
2.

How do you take your coffee?

Sissung TM, Huang PA, Strope JD, Figg WD.

Lancet Oncol. 2019 Jul;20(7):913-914. doi: 10.1016/S1470-2045(19)30387-0. No abstract available.

PMID:
31267961
3.

Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.

Sissung TM, Huang PA, Hauke RJ, McCrea EM, Peer CJ, Barbier RH, Strope JD, Ley AM, Zhang M, Hong JA, Venzon D, Jackson JP, Brouwer KR, Grohar P, Glod J, Widemann BC, Heller T, Schrump DS, Figg WD.

Mol Pharmacol. 2019 Aug;96(2):158-167. doi: 10.1124/mol.118.114827. Epub 2019 Jun 7.

4.

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.

Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM.

Oncotarget. 2019 Apr 23;10(30):2855-2868. doi: 10.18632/oncotarget.26869. eCollection 2019 Apr 23.

5.

First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.

Kurdziel KA, Mena E, McKinney Y, Wong K, Adler S, Sissung T, Lee J, Lipkowitz S, Lindenberg L, Turkbey B, Kummar S, Milenic DE, Doroshow JH, Figg WD, Merino MJ, Paik CH, Brechbiel MW, Choyke PL.

J Transl Sci. 2019 Apr;5(2). doi: 10.15761/JTS.1000269. Epub 2018 Jul 13.

6.

Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer.

Sissung TM, Rajan A, Blumenthal GM, Liewehr DJ, Steinberg SM, Berman A, Giaccone G, Figg WD.

PLoS One. 2019 Feb 28;14(2):e0212097. doi: 10.1371/journal.pone.0212097. eCollection 2019.

7.

Insulin potentiation therapy for cancer?

Sissung TM, Schmidt KT, Figg WD.

Lancet Oncol. 2019 Feb;20(2):191-192. doi: 10.1016/S1470-2045(19)30003-8. No abstract available.

PMID:
30712796
8.

Alam K et al. (2018) Drug Metabolism Letters; 12, 24-32.

Sissung TM, Chau C, Price DK, Figg WD.

Drug Metab Lett. 2018;12(2):153. doi: 10.2174/1872312812999180724145725.

PMID:
30598062
9.

Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization.

Levy EB, Peer C, Sissung TM, Venkatesan A, Pandalai P, Greten T, Hughes MS, Garcia C, Peretti J, Figg W, Lewis A, Wood B.

J Vasc Interv Radiol. 2019 Jan;30(1):19-22. doi: 10.1016/j.jvir.2018.06.023. Epub 2018 Dec 6.

PMID:
30527657
10.

Precision medicine applications in prostate cancer.

McCrea EM, Lee DK, Sissung TM, Figg WD.

Ther Adv Med Oncol. 2018 Jun 18;10:1758835918776920. doi: 10.1177/1758835918776920. eCollection 2018. Review.

11.

A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat.

Peer CJ, Hall OM, Sissung TM, Piekarz R, Balasubramaniam S, Bates SE, Figg WD.

Cancer Chemother Pharmacol. 2018 Sep;82(3):565-570. doi: 10.1007/s00280-018-3631-7. Epub 2018 Jun 27.

12.

Association Between Thiopurine S-Methyltransferase (TPMT) Genetic Variants and Infection in Pediatric Heart Transplant Recipients Treated With Azathioprine: A Multi-Institutional Analysis.

Green DJ, Duong SQ, Burckart GJ, Sissung T, Price DK, Figg WD Jr, Brooks MM, Chinnock R, Canter C, Addonizio L, Bernstein D, Naftel DC, Zeevi A, Kirklin JK, Webber SA, Feingold B.

J Pediatr Pharmacol Ther. 2018 Mar-Apr;23(2):106-110. doi: 10.5863/1551-6776-23.2.106.

13.

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.

Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC.

Oncotarget. 2017 Mar 25;8(45):79175-79187. doi: 10.18632/oncotarget.16577. eCollection 2017 Oct 3.

14.

Pharmacogenomics Implementation at the National Institutes of Health Clinical Center.

Sissung TM, McKeeby JW, Patel J, Lertora JJ, Kumar P, Flegel WA, Adams SD, Eckes EJ, Mickey F, Plona TM, Mellot SD, Baugher RN, Wu X, Soppet DR, Barcus ME, Datta V, Pike KM, DiPatrizio G, Figg WD, Goldspiel BR.

J Clin Pharmacol. 2017 Oct;57 Suppl 10:S67-S77. doi: 10.1002/jcph.993. Review.

15.

A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.

Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ, Widemann BC.

Cancer Chemother Pharmacol. 2017 Sep;80(3):645-652. doi: 10.1007/s00280-017-3382-x. Epub 2017 Jul 22.

16.

Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients.

Hauke RJ Jr, Sissung TM, Figg WD.

Cancer Biol Ther. 2017 Aug 3;18(8):545-546. doi: 10.1080/15384047.2017.1345398. Epub 2017 Jul 5.

17.

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.

Sissung TM, Peer CJ, Korde N, Mailankody S, Kazandjian D, Venzon DJ, Landgren O, Figg WD.

Cancer Chemother Pharmacol. 2017 Jul;80(1):217-221. doi: 10.1007/s00280-017-3323-8. Epub 2017 May 9.

18.

Cellular identity crisis: Antiandrogen resistance by lineage plasticity.

Tuerff D, Sissung T, Figg WD.

Cancer Biol Ther. 2017 Nov 2;18(11):841-842. doi: 10.1080/15384047.2017.1323599. Epub 2017 May 5.

19.

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.

Sissung TM, Ley AM, Strope JD, McCrea EM, Beedie S, Peer CJ, Shukla S, van Velkinburgh J, Reece K, Troutman S, Campbell T, Fernandez E, Huang P, Smith J, Thakkar N, Venzon DJ, Brenner S, Lee W, Merino M, Luo J, Jager W, Price DK, Chau CH, Figg WD.

Mol Cancer Res. 2017 Aug;15(8):1096-1105. doi: 10.1158/1541-7786.MCR-16-0477. Epub 2017 Apr 7.

20.

Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer.

Sissung TM, Deeken J, Leibrand CR, Price DK, Ehrlich S, Steinberg SM, Liewehr DJ, Dahut W, Figg WD.

Pharmacogenomics. 2016 Dec;17(18):1979-1986. Epub 2016 Nov 24.

Supplemental Content

Loading ...
Support Center